Schroder Investment Management Group
ABUS icon

Schroder Investment Management Group’s Arbutus Biopharma ABUS Stock Holding History

Schroder Investment Management Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-121,313
Closed -$522K – 1168
2026
Q1 		$522K Hold
121,313
– – ﹤0.01% 1089
2025
Q4 		$560K Hold
121,313
– – ﹤0.01% 1048
2025
Q3 		$541K Hold
121,313
– – ﹤0.01% 1085
2025
Q2 		$375K Buy
+121,313
New +$403K ﹤0.01% 1078

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Schroder Investment Management Group's ABUS Position: Q2 2026 in Review

Schroder Investment Management Group sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 121,313 shares — an estimated $522K sold.

Schroder Investment Management Group first reported a position in ABUS in Q2 2025 and held it in 4 quarters. The position peaked at $560K in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Schroder Investment Management Group reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • Schroder Investment Management Group sold 121,313 Arbutus Biopharma shares in Q2 2026, an estimated $522K.
  • Schroder Investment Management Group first reported a position in Arbutus Biopharma in Q2 2025 and held it in 4 quarters.
  • Schroder Investment Management Group's Arbutus Biopharma position peaked at $560K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.